Integrating the Results of Phase IV ( Postmarketing ) Clinical Trial With Four Previous Trials Reinforces the Position that Regranex ( Becaplermin ) Gel 0 . 01 % Is an Effective Adjunct to the Treatment of Diabetic Foot Ulcers

@inproceedings{Robson2005IntegratingTR,
  title={Integrating the Results of Phase IV ( Postmarketing ) Clinical Trial With Four Previous Trials Reinforces the Position that Regranex ( Becaplermin ) Gel 0 . 01 % Is an Effective Adjunct to the Treatment of Diabetic Foot Ulcers},
  author={Martin C. Robson and Wyatt G. Payne and Warren Louis Garner and Joseph J. Biundo and Vincent F. Giacalone and Diane M. Cooper and Peter Ouyang},
  year={2005}
}
Background: Platelet-derived growth factor (PDGF) has been demonstrated in pre-clinical studies to promote granulation tissue and stimulate cutaneous ulcer healing. Becaplermin gel 100 μg/g is the commercial preparation of the PDGF-BB homodimer and has been Robson-vol5no1 3/19/05 11:17 AM Page 35 
14 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Effects of transforming growth factor B2 on wound healing in diabetic foot ulcers: A randomized controlled safety and dose-ranging trial

  • MC Robson, DL Steed, JM McPherson
  • J Appl Res
  • 2002

Platelet-derived growth factor in the treatment of diabetic foot ulcers

  • DL Steed
  • Wounds
  • 2000

Similar Papers

Loading similar papers…